Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling

Por Diermeier-Daucher, Simone, Ortmann, Olaf, Buchholz, Stefan, Brockhoff, Gero
Publicado em 2012

The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients

Por Machleidt, Anna, Buchholz, Stefan, Diermeier-Daucher, Simone, Zeman, Florian, Ortmann, Olaf, Brockhoff, Gero
Publicado em 2013

Presence of HER4 associates with increased sensitivity to Herceptin™ in patients with metastatic breast cancer

Por Sassen, Andrea, Diermeier-Daucher, Simone, Sieben, Manuela, Ortmann, Olaf, Hofstaedter, Ferdinand, Schwarz, Stephan, Brockhoff, Gero
Publicado em 2009

The inhibition of tyrosine kinase receptor signalling in leiomyosarcoma cells using the small molecule kinase inhibitor PTK787/ZK222584 (Vatalanib(®))

Por GAUMANN, ANDREAS K.A., DREXLER, HANNES C.A., LANG, SVEN A., STOELTZING, OLIVER, DIERMEIER-DAUCHER, SIMONE, BUCHDUNGER, ELISABETH, WOOD, JEANETTE, BOLD, GUIDO, BREIER, GEORG
Publicado em 2014